Application: TCR(m) Drug Development in immuno-oncology 

BioCopy is a multinational company headquartered in Switzerland with a large and modern R&D facility in Germany. The company provides high-throughput analyses for the development of immunotherapeutics and novel vaccines in the field of oncology and infectious diseases. BioCopy focuses on the development of TCR(m)-based immuno-oncology drugs.

The BioCopy platform technology is based on a patented process for the fabrication of complex microarrays. They comprise thousands of complex biological molecules such as pHLAs used for efficacy screening of immuno-oncology drug candidates, in particular TCR(m).
The heart of the platform is the proprietary SCORE (Single COlor REflectometry) technology, which needs perfect arrays for the precise measurement of every single spot on the microarray.

Insertion of array into SCORE device. Copyright BioCopy GmbH.


The iTWOs by M2 work hand in glove with BioCopy’s cutting-edge technology for the fabrication of high-quality microarrays. The printers of M2-Automation complement the BioCopy process perfectly.

Spotting of microarrays. Copyright BioCopy GmbH.